论文部分内容阅读
对30例慢性哮喘须依赖口服皮质激素治疗的患者,应用氯地米松气雾剂治疗,观察其临床疗效和下丘脑—垂体—肾上腺功能恢复情况。病员随机分两组,治疗组16例,男10例,女6例,年龄50.4(±13.7)岁,病程10.6(±10.3)年。FEV_1预计值53.8±23.14％。依赖皮质素治疗2.6(±1.9)年,每日强的松用量11.4(±5.7)毫克,对照组14例,男7例,女7例,年龄54.9(±9.5)岁,病程16.1(±14.5)年,FEV_1预计值50.8±20.9％,依赖皮质素治疗6.2(±4.3)年,每日强的松用量15.4(±4.8)毫克。第一阶段进行双盲试验:治疗组应用氯地米松400微克/日,分4次吸入,治疗1周后,逐渐减少强
Thirty patients with chronic asthma who were dependent on oral corticosteroids were treated with dexamethasone aerosol. The clinical efficacy and recovery of hypothalamus-pituitary-adrenal function were observed. The patients were randomly divided into two groups. The treatment group consisted of 16 patients, 10 males and 6 females, with a mean age of 50.4 (± 13.7 years) and a duration of 10.6 (± 10.3) years. FEV_1 is expected to be 53.8 ± 23.14%. Dependent on corticosteroids 2.6 (± 1.9) years, the daily amount of prednisone 11.4 (± 5.7) mg in the control group of 14 patients, 7 males and 7 females, age 54.9 (± 9.5) years of age, duration of 16.1 (± 14.5 ) Year, FEV_1 is estimated to be 50.8 ± 20.9%, with prednisone 15.4 (± 4.8) mg daily for 6.2 (± 4.3) years of corticosteroid treatment. The first phase of double-blind trial: the treatment group, the use of beclometasone 400 micrograms / day, divided into 4 inhalations, after 1 week of treatment, and gradually reduce the strong